시장보고서

상품코드

1761163

세포 및 유전자 치료 CDMO 시장 : 시장 규모, 예측, 점유율, 동향, 성장기회 분석 보고서 - 서비스 유형별, 제품 유형별, 최종 사용자별, 지역별(2021-2031년)

Cell and Gene Therapy Contract Development and Manufacturing Organization Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type, Product Type, End User, and Geography

발행일: 2025년 06월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 249 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당사의 최신 조사 보고서 '세계의 세포 및 유전자 치료 CDMO 시장 예측 및 분석-서비스 유형별, 제품 유형별, 최종 사용자별, 지역별(-2031년)」에 의하면, 시장은 2024년의 62억 2,000만 달러로 평가되었고, 2031년에는 318억 6,000만 달러에 이를 것으로 예측되며, 2025-2031년 26.4%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 혁신적인 치료법 임상시험 개척, 규제당국에 의한 승인 및 상업화의 급증이 세포 및 유전자 치료 CDMO 시장 규모 확대에 기여하고 있습니다. 그러나 제조의 복잡성이 세포 및 유전자 치료 CDMO 시장의 성장을 저해하고 있습니다. 게다가 AI와 디지털 전환의 통합 고조는 향후 수년간 새로운 세포 및 유전자 치료 CDMO 시장의 동향을 가져올 것으로 예상됩니다.

수익면에서는 북미가 2024년 시장을 독점했습니다. 예측 기간 동안에도 세계 시장을 독점할 것으로 예측됩니다. 미국은 세계 최대의 세포 및 유전자 치료 CDMO 시장입니다. 미국에서는 바이오 기술의 진보, 유전성 질환 증가, 전문적인 제조 서비스에 대한 수요 급증이 관찰되고 있습니다. 2021년 10월에 발표된 미국 정부책임국의 추계에 따르면 미국에서는 2,500만 명에서 3,000만 명이 희귀질환에 시달리고 있습니다. 식품의약국(FDA)에 따르면 7,000개 이상의 희귀 질병이 국내 3,000만 명 이상의 사람들에게 영향을 미치고 있습니다. 이러한 질환에 대한 이해가 깊어지면서 유전자 치료 개발이 급증하고 있습니다. CDMO는 희귀 유전 질환을 대상으로 한 유전자 치료 개발 및 제조에 특화된 서비스를 제공함으로써 이 분야에서 중요한 역할을 하고 있습니다.

2023년 미국 FDA는 희귀질환을 표적으로 한 유전자 편집 치료를 포함한 수많은 세포 및 유전자 치료를 승인했습니다. 겸상적혈구증에 대한 exagamglogene autotemcel(Casgevy)과 lovotibeglogene autotemcel, 중증혈우병 A에 대한 valoctocogene roxaparvovec 등의 치료제가 FDA 승인을 받았으며 희귀질환의 과제에 대한 유전자 치료 가능성을 부각시키고 있습니다. 재생 의료 선진 요법(RMAT)과 같은 규제 완화의 가속화에 의해, 바이오 테크놀로지 기업은 CDMO와 제휴해 생산을 확대하는 경향에 있습니다.

제조 인프라에 대한 투자가 시장 성장을 뒷받침하고 있습니다. 15개의 학술 연구 기관, 25개 이상의 기업, 정부 기관의 협력에 의해 설립된 National Cell Manufacturing Consortium은 세포 치료의 비용 효율적인 대규모 제조를 가능하게 하는 것을 목적으로 하고 있습니다. 게다가 CDMO, 학술 기관, 바이오 의약품 기업간의 전략적 제휴도 시장 성장에 기여하고 있습니다.

세포 및 유전자 치료 CDMO 시장 분석

전문 시설과 기술에 대한 접근이 향후 시장 기회를 제공

세포 및 유전자 치료제 수요는 바이오 의약품 기업을, 품질, 컴플라이언스, 규제 당국의 승인을 확보하면서 생산을 확대하기 위해서 필요한 최첨단의 시설이나 기술을 제공할 수 있는 CDMO에 향하게 하고 있습니다. 이러한 전문적 능력은 높은 제조 기준을 유지하기 위해 고도의 인프라를 필요로 하는 복잡하고 개별화된 치료법의 제조에 필수적입니다. 유전자 편집, 바이러스 벡터 생산, 개별화 의료를 포함한 세포 및 유전자 치료에는 최신 기술을 갖춘 전문 시설이 필요합니다. 유전자 치료에 사용되는 바이러스 벡터 제조에는 최종 제품의 안전성, 일관성, 품질을 확보하기 위해 GMP 기준 시설이 필요합니다. 이러한 시설은 살아있는 세포나 유전자 변형 생물 등의 복잡한 생물학적 재료를 제어되고 감시된 환경에서 다루기 위한 설비를 갖추고 있어야 합니다. 자동화된 세포 배양 시스템, 연속 제조, 디지털 품질 감시 시스템의 채택이 증가하고 있는 것은 유전자 치료 생산의 성장과 효율을 높이고 있습니다. 예를 들어 2025년 3월 바라트 바이오텍은 인도 남부에서 첫 세포 및 유전자 치료 시설에 7,500만 달러를 투자했으며, 향후 3년 이내에 종양학과 희귀질환을 위한 새로운 치료법을 출시할 예정입니다.

전문 시설의 필요성은 CDMO에 있어 큰 기회입니다. 바이오파마 기업에 있어서, 필요한 기술이나 시설을 가지는 CDMO와 제휴하는 것은, 비용대비 효과가 높고 효율적입니다. 예를 들어, 2023년 브리스톨 마이어스 스퀴브는 CAR-T 세포 요법인 브리앙지의 제조를 위해 CDMO와 제휴했습니다. 이 치료법은 환자의 T세포를 채취, 수정, 확대하는 것으로 바람직한 치료 효과를 확보하기 위해서는 전문적인 기술과 설비를 필요로 하는 과정입니다. 브리스톨 마이어스 스퀴브사는 전문 시설에서 CDMO의 전문 지식을 활용함으로써 규제 준수와 품질을 확보하면서 생산 규모를 확대할 수 있었습니다. 이와 같이 첨단 기술을 구사한 고도의 제조능력에 대한 요구의 증대는 세포 및 유전자 치료 CDMO 시장에 장래의 성장 기회를 가져올 것으로 예상됩니다.

세포 및 유전자 치료 CDMO 시장 보고서 세분화 분석

세포 및 유전자 치료 CDMO 시장 분석의 도출에 기여한 주요 부문은 서비스 유형, 제품 유형, 최종 사용자입니다.

서비스 유형에 따라 세포 및 유전자 치료 CDMO 시장은 의약품 개발 및 제조, 시험 및 규제 서비스, 기타로 구분됩니다. 의약품 개발 및 제조 부문은 2024년에 시장에서 최대의 점유율을 차지했습니다.

제품 유형별로는 세포 및 유전자 치료 CDMO 시장은 유전자치료와 세포치료로 2분됩니다. 2024년에는 세포치료 분야가 시장을 독점했습니다.

최종 사용자별로는 세포 및 유전자 치료 CDMO 시장은 제약기업, 바이오제약기업, 기타로 분류됩니다. 2024년에는 바이오 제약 기업 부문이 시장을 독점했습니다.

세포 및 유전자 치료 CDMO 시장 : 경쟁 구도와 주요 발전

WuXi Biologics Inc, Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, Thermo Fisher Scientific Inc, AGC Biologics AS, Takara Bio Inc, FUJIFILM Holdings Corp, Pluri Inc, SK pharmteco Inc, Aenova Holding GmbH, Minaris Advanced Therapies 등이 세포 및 세포 및 유전자 치료 CDMO 시장에서 사업을 전개하고 있는 주요 기업입니다.

캐나다 통계국(Statistics Canada), 세계 인구 전망(World Population Prospectus), Globocan, 브라질 보건 규제청(ANVISA), 재생 의료 연합(ARM), 식품 의약품국(FDA) 등은 세포 및 유전자 치료 CDMO 시장 보고서를 작성할 때 참조한 1차 정보원 및 2차 정보원입니다.

세포 및 세포 및 유전자 치료 CDMO 시장-주요 시장 역학
시장 성장 촉진요인
- 혁신적 치료를 위한 임상시험 증가
- 규제 당국에 의한 승인 및 상업화의 급증
시장 성장 억제요인
- 제조의 복잡성
시장 기회
- 전문 시설 및 기술에 대한 액세스
향후 동향
- AI와 디지털 전환의 통합 증가
성장 촉진요인 및 억제요인의 영향

제6장 세계의 세포 및 유전자 치료 CDMO 시장 : 시장 분석

세포 및 유전자 치료 CDMO 시장의 매출액(2021-2031년)
세포 및 유전자 치료 CDMO 시장 예측 분석

제7장 세포 및 유전자 치료 CDMO 시장 분석 : 서비스 유형별

의약품 개발 및 제조
시험 및 약사 서비스
기타

제8장 세포 및 유전자 치료 CDMO 시장 분석 : 제품 유형별

유전자 치료
세포 치료

제9장 세포 및 유전자 치료 CDMO 시장 분석 : 최종 사용자별

제약회사
바이오의약품기업
기타

제10장 세포 및 유전자 치료 CDMO 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 스페인
- 이탈리아
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 아시아태평양의 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 경쟁 구도

세계 기업 점유율 분석(2024년)

제12장 업계 정세

사업 확대
신제품 개발
합병 및 인수
파트너십
기타 사업 전략

제13장 기업 프로파일

WuXi Biologics Inc
Charles River Laboratories International Inc
Catalent Inc
Lonza Group AG
Thermo Fisher Scientific Inc.
AGC Biologics AS
Takara Bio Inc
FUJIFILM Holdings Corp
Pluri Inc
SK pharmteco Inc
Aenova Holding GmbH
Minaris Advanced Therapies

제14장 부록

AJY 25.07.10

According to our new research study on "Cell and Gene Therapy Contract Development and Manufacturing Organization Market Forecast to 2031 -Global Analysis - by Service Type, Product Type, End User, and Geography," the market is anticipated to grow from US$ 6.22 billion in 2024 and is projected to reach US$ 31.86 billion by 2031; it is expected to register a CAGR of 26.4% during 2025-2031. Increasing clinical trials for innovative therapies and surging regulatory approvals and commercialization are contributing to the growing cell and gene therapy contract development and manufacturing organization market size. However, the high manufacturing complexities hampers the cell and gene therapy contract development and manufacturing organization market growth. Further, rising integration of AI and digital transformation is expected to bring in new cell and gene therapy contract development and manufacturing organization market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for cell and gene therapy contract development and manufacturing organization in the world. The US is observing growing advancements in biotechnology, an increasing prevalence of genetic diseases, and surging demand for specialized manufacturing services. As per the estimates of the US Government Accountability Office published in October 2021, ~25 to 30 million people suffer from rare diseases in the country. As per the Food and Drug Administration (FDA), more than 7,000 rare diseases affect over 30 million people in the country. The growing understanding of these diseases has led to a surge in gene therapy development. CDMOs play a crucial role in this space by providing specialized services for the development and manufacturing of gene therapies targeting rare genetic disorders.

In 2023, the US FDA approved numerous cell and gene therapies, including gene-editing treatments targeting rare diseases. Therapies such as exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel for sickle cell disease, as well as valoctocogene roxaparvovec for severe hemophilia A, have received FDA approval, highlighting the potential of gene therapies in addressing rare disease challenges. The accelerated regulatory pathways, such as the Regenerative Medicine Advanced Therapy (RMAT) designation, have spurred biotechnology companies to partner with CDMOs for scaling production.

Investments in manufacturing infrastructure have bolstered the market growth. The National Cell Manufacturing Consortium, established through collaboration between 15 academic institutes, over 25 companies, and government agencies, aims to enable cost-effective, large-scale manufacturing of cell therapies. In addition, strategic collaborations between CDMOs, academic institutions, and biopharma companies also contribute to market growth.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market Analysis

Access to Specialized Facilities and Technologies to Provide Market Opportunities in Future

The demand for cell and gene therapies is driving biopharmaceutical companies toward CDMOs that can provide cutting-edge facilities and technologies, which are required to scale up production while ensuring quality, compliance, and regulatory approval. These specialized capabilities are essential for the production of complex and personalized therapies, which require advanced infrastructure to maintain high manufacturing standards. Cell and gene therapies, including gene editing, viral vector production, and personalized medicine, require specialized facilities equipped with the latest technologies. The production of viral vectors used in gene therapies requires GMP standard facilities to ensure the safety, consistency, and quality of the final product. These facilities should be equipped to handle complex biological materials, such as live cells and genetically modified organisms, in controlled and monitored environments. The increasing adoption of automated cell culture systems, continuous manufacturing, and digital quality monitoring systems enhances the growth and efficiency of gene therapy production. For instance, in March 2025, Bharat Biotech invested US$ 75 million in its first cell and gene therapy facility in the southern India which is expected to launch new therapies in next 3 years for oncology and rare disease.

The need for specialized facilities creates a substantial opportunity for CDMOs. It is cost-effective and efficient for biopharma companies to collaborate with CDMOs that have the required technology and facilities. For instance, in 2023, Bristol-Myers Squibb collaborated with a CDMO for the production of its CAR-T cell therapy, Breyanzi. This therapy involves harvesting, modifying, and expanding a patient's T-cells, a process requiring specialized technology and facilities to ensure the desired therapeutic effect. By leveraging CDMO expertise in specialized facilities, Bristol-Myers Squibb was able to scale production while ensuring regulatory compliance and quality. Thus, the soaring need for advanced manufacturing capabilities with advanced technology is expected to create future growth opportunities for the cell and gene therapy contract research and development organization market.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market Report Segmentation Analysis

Key segments that contributed to the derivation of the cell and gene therapy contract development and manufacturing organization market analysis are service type, product type, and end user.

Based on service type, the cell and gene therapy contract development and manufacturing organization market is segmented into drug development and manufacturing, testing and regulatory services, and others. The drug development and manufacturing segment held the largest share of the market in 2024.

In terms of product type, the cell and gene therapy contract development and manufacturing organization market is bifurcated into gene therapy and cell therapy. The cell therapy segment dominated the market in 2024.

By end user, the cell and gene therapy contract development and manufacturing organization market is categorized into pharmaceutical companies, biopharmaceutical companies, and others. The biopharmaceutical companies segment dominated the market in 2024.

Cell and Gene Therapy Contract Development and Manufacturing Organization Market: Competitive Landscape and Key Developments

WuXi Biologics Inc, Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, Thermo Fisher Scientific Inc., AGC Biologics AS, Takara Bio Inc, FUJIFILM Holdings Corp, Pluri Inc, SK pharmteco Inc, Aenova Holding GmbH, and Minaris Advanced Therapies are among the key companies operating in the cell and gene therapy contract development and manufacturing organization market.

Statistics Canada, World Population Prospectus, Globocan, Brazilian Health Regulatory Agency (ANVISA), Alliance for Regenerative Medicine (ARM), and the Food and Drug Administration (FDA) are among the primary and secondary sources referred to while preparing the cell and gene therapy contract development and manufacturing organization market report.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Landscape

4.1 Overview
4.2 Global Plasmid Manufacturing Market

5. Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics

5.1 Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Clinical Trials for Innovative Therapies
- 5.2.2 Surging Regulatory Approvals and Commercialization
5.3 Market Restraints
- 5.3.1 High Manufacturing Complexities
5.4 Market Opportunities
- 5.4.1 Access to Specialized Facilities and Technologies
5.5 Future Trends
- 5.5.1 Rising Integration of AI and Digital Transformation
5.6 Impact of Drivers and Restraints:

6. Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Global Market Analysis

6.1 Cell And Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2021-2031
6.2 Cell And Gene Therapy Contract Development and Manufacturing Organization Market Forecast Analysis

7. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Analysis - by Service Type

7.1 Drug Development and Manufacturing
- 7.1.1 Overview
- 7.1.2 Drug Development and Manufacturing: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Testing and Regulatory Services
- 7.2.1 Overview
- 7.2.2 Testing and Regulatory Services: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Others
- 7.3.1 Overview
- 7.3.2 Others: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)

8. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Analysis - by Product Type

8.1 Gene Therapy
- 8.1.1 Overview
- 8.1.2 Gene Therapy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Cell Therapy
- 8.2.1 Overview
- 8.2.2 Cell Therapy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)

9. Cell And Gene Therapy Contract Development and Manufacturing Organization Market Analysis - by End User

9.1 Pharmaceutical Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical Companies: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Biopharmaceutical Companies
- 9.2.1 Overview
- 9.2.2 Biopharmaceutical Companies: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast to 2031 (US$ Million)

10. Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.2.2 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.2.2.1 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.2.2.2 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.2.2.3 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.2.3 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.1 North America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.2.3.2 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.2.3.2.1 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.2.3.2.2 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.2.3.2.3 United States: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.2.3.3 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.2.3.3.1 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.2.3.3.2 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.2.3.3.3 Canada: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.2.3.4 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.2.3.4.1 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.2.3.4.2 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.2.3.4.3 Mexico: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.3 Europe
- 10.3.1 Europe Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.3.2 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.3.2.1 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.3.2.2 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.3.2.3 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.3.3 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.1 Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.3.3.2 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.2.1 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.2.2 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.2.3 Germany: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.3 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.3.1 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.3.2 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.3.3 United Kingdom: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.4 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.4.1 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.4.2 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.4.3 France: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.5 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.5.1 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.5.2 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.5.3 Spain: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.6 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.6.1 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.6.2 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.6.3 Italy: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.3.3.7 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.3.3.7.1 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.3.3.7.2 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.3.3.7.3 Rest of Europe: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.4 Asia Pacific
- 10.4.1 Asia Pacific Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.4.2 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.4.2.1 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.4.2.2 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.4.2.3 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.4.3 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.1 Asia Pacific: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.4.3.2 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.2.1 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.2.2 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.2.3 China: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.3 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.3.1 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.3.2 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.3.3 Japan: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.4 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.4.1 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.4.2 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.4.3 India: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.5 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.5.1 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.5.2 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.5.3 Australia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.6 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.6.1 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.6.2 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.6.3 South Korea: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.4.3.7 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.4.3.7.1 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.4.3.7.2 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.4.3.7.3 Rest of APAC: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.5.2 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.5.2.1 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.5.2.2 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.5.2.3 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
- 10.5.3 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.1 Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.5.3.2 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.2.1 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.2.2 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.2.3 Saudi Arabia: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.5.3.3 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.3.1 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.3.2 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.3.3 South Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.5.3.4 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.4.1 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.4.2 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.4.3 United Arab Emirates: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.5.3.5 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.5.3.5.1 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.5.3.5.2 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.5.3.5.3 Rest of Middle East and Africa: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
10.6 South and Central America
- 10.6.1 South and Central America Cell And Gene Therapy Contract Development and Manufacturing Organization Market Overview
- 10.6.2 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
  - 10.6.2.1 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Service Type
  - 10.6.2.2 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Product Type
  - 10.6.2.3 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by End User
  - 10.6.2.4 South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast Analysis - by Country
  - 10.6.2.5 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.6.2.5.1 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.6.2.5.2 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.6.2.5.3 Brazil: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.6.2.6 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.6.2.6.1 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.6.2.6.2 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.6.2.6.3 Argentina: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User
  - 10.6.2.7 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market - Revenue, 2021 - 2031 (US$ Million)
    - 10.6.2.7.1 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Service Type
    - 10.6.2.7.2 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by Product Type
    - 10.6.2.7.3 Rest of South and Central America: Cell And Gene Therapy Contract Development and Manufacturing Organization Market Breakdown, by End User

11. Competitive Landscape

11.1 Global Company Market Share Analysis, 2024

12. Industry Landscape

12.1 Overview
12.2 Expansion
12.3 New Product Development
12.4 Merger and Acquisition
12.5 Partnerships
12.6 Other Business Strategies

13. Company Profiles

13.1 WuXi Biologics Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Charles River Laboratories International Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Catalent Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Lonza Group AG
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AGC Biologics AS
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Takara Bio Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 FUJIFILM Holdings Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Pluri Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 SK pharmteco Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Aenova Holding GmbH
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments
13.12 Minaris Advanced Therapies
- 13.12.1 Key Facts
- 13.12.2 Business Description
- 13.12.3 Products and Services
- 13.12.4 Financial Overview
- 13.12.5 SWOT Analysis
- 13.12.6 Key Developments

14. Appendix

14.1 Glossary of Terms
14.2 About The Insight Partners